Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow

Protagonist Therapeutics,Inc.
Posted on: 01 Mar 18
Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow

PR Newswire

NEWARK, Calif., March 1, 2018

NEWARK, Calif., March 1, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a biopharmaceutical company developing novel peptide-based drugs to address significant unmet medical needs, will announce fourth quarter and year-end 2017 financial results after the NASDAQ market closes on Wednesday, March 7, 2018. Protagonist management will host a year-end update call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time the same day.

Conference Call and Webcast Details:

Date: Wednesday, March 7, 2018

Time: 4:30 PM (ET) / 1:30 PM (PT)

US/CANADA Toll-free: (844) 515-9178

International: (614) 999-9313

Conference ID: 4054387

Webcast URL: www.protagonist-inc.com under "Events & Presentations" on the Investors page of the company's website

About Protagonist Therapeutics

Protagonist Therapeutics is a clinical development-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. Its primary focus is to develop potential first-in-class oral gastrointestinal (GI) restricted targeted therapies that block validated biological pathways currently targeted by marketed injectable antibody drugs. Our lead peptide candidates, PTG-100 and PTG-200, are oral targeted therapy drugs being developed for inflammatory bowel diseases (IBD). The alpha-4-beta-7 integrin antagonist peptide PTG-100 is currently in a Phase 2b clinical trial for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist peptide PTG-200 is currently being studied in a Phase 1 clinical trial in healthy volunteers to support further development in Crohn's disease.  Both alpha-4-beta-7 integrin and IL-12/23 pathway blockade are approaches that have been validated through FDA-approved injectable antibody drugs. The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200.  Protagonist has also applied its versatile platform outside of the GI disease areas and is developing an injectable hepcidin mimetic, PTG-300, for the potential treatment of rare blood diseases such as beta-thalassemia and myelodysplastic syndromes (MDS). PTG-300 recently completed a Phase 1 clinical trial where we achieved a pharmacodynamic-based clinical proof-of-concept in normal healthy volunteers.

Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/protagonist-to-announce-fourth-quarter-and-year-end-2017-financial-results-on-march-7-2018-year-end-update-call-to-follow-300606465.html

SOURCE Protagonist Therapeutics, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 01/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.